Herba artemisiae scopariae dampness-clearing traditional Chinese medicine composition as well as preparation method and application thereof

Through the preparation of Yinling Chinese medicine composition for damp-removing and the use of the effects of Chinese medicinal materials such as Poria cocos, the problem of poor treatment effect of damp-like metabolic syndrome is solved, and the regulation of effective reduction of BMI, improved damp-like syndrome levels, blood lipids and blood pressure is achieved. , ensuring safety and improving the effectiveness of traditional Chinese medicine treatment.

CN118924869AActive Publication Date: 2024-11-12GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Patent Information

Application Number
CN202411015332.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12
Estimated Expiration
2044-07-26

AI Technical Summary

Technical Problem

The existing Chinese medicine has poor effect on the treatment of damp-like metabolic syndrome, which leads to patients taking a variety of Western medicines, which can easily cause drug interactions and adverse reactions and affect the quality of life.

Method used

Develop a traditional Chinese medicine composition for removing dampness, including Poria cocos, Atractylodes macrocephala, Poria cocos, Cinnamon twig, Dried ginger, Licorice, Yinchen and Northern Salvia, and prepare granules through decoction, concentration under reduced pressure, spray drying and other processes. It is used to strengthen the spleen and promote diuresis, exudate dampness, warm the middle and benefit the stomach, and is used to treat metabolic syndromes of spleen and stomach deficiency and endogenous dampness.

Benefits of technology

Effectively reduce BMI, improve wet syndrome level, reduce waist and hip circumference, regulate blood lipids, lower blood pressure, significantly reduce triglyceride levels, increase high-density lipoprotein cholesterol levels, significantly reduce systolic blood pressure and diastolic blood pressure, and is safe and safe, without Significant serious adverse events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004965522390000051
    Figure BDA0004965522390000051
  • Figure BDA0004965522390000061
    Figure BDA0004965522390000061
  • Figure BDA0004965522390000081
    Figure BDA0004965522390000081
Patent Text Reader

Abstract

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a herba artemisiae scopariae dampness-clearing traditional Chinese medicine composition as well as a preparation method and application thereof. The herba artemisiae scopariae dampness-clearing traditional Chinese medicine composition is prepared from the following active ingredients in parts by mass: 30 to 60 parts of poria cocos, 10 to 30 parts of rhizoma atractylodis macrocephalae, 10 to 30 parts of polyporus umbellatus, 10 to 30 parts of cassia twig, 5 to 10 parts of rhizoma zingiberis, 10 to 30 parts of liquorice root, 10 to 30 parts of herba artemisiae scopariae and 10 to 30 parts of radix glehniae. Clinical tests show that the herba artemisiae scopariae dampness-clearing traditional Chinese medicine composition can effectively reduce BMI of people suffering from the metabolic syndrome due to the dampness syndrome and effectively improve the level of the dampness syndrome, has an obvious effect on reduction of the waistline and the hipline, enables the body weight to have a certain decline trend, can remarkably lower the triglyceride level and increase the high-density lipoprotein cholesterol level, and has the effects of clearing away heat and toxic materials. The systolic pressure and diastolic pressure levels can be obviously reduced, and the safety is good. Therefore, the herba artemisiae scopariae dampness-clearing traditional Chinese medicine composition disclosed by the invention has a very good treatment effect on the dampness-syndrome metabolic syndrome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of traditional Chinese medicine, and particularly relates to a Yinling dehumidifying traditional Chinese medicine composition and a preparation method and application thereof. Background Art

[0002] Metabolic syndrome (MetS) is a combination of metabolically interrelated risk factors that directly contribute to the occurrence of cardiovascular and cerebrovascular diseases such as atherosclerotic cardiovascular disease, ischemic stroke, and type 2 diabetes. With the improvement of modern living standards, the incidence of metabolic syndrome has been rising around the world.

[0003] Western medicine treatment mainly intervenes in different metabolic abnormalities through various drugs such as hypoglycemic drugs, antihypertensive drugs, lipid-lowering drugs, etc. Long-term use of Western medicine may lead to adverse reactions such as gastrointestinal discomfort and liver and kidney damage. At the same time, due to the coexistence of multiple abnormal factors, patients with metabolic syndrome often need to take multiple drugs at the same time, which is easy to cause interactions between drugs, which may pose a potential threat to the patient's physical health and affect the patient's quality of life to a certain extent.

[0004] Traditional Chinese medicine, based on the holistic concept and the characteristics of individualized syndrome differentiation and treatment, can play an important role in the diagnosis and treatment of metabolic syndrome. It has the advantages of precision, individualization, and few adverse reactions, and has good application prospects. At present, there are many traditional Chinese medicines used to treat metabolic syndrome in clinical practice, such as Tianqi Jiangtang Capsule, Erchen Decoction combined with Taohong Siwu Decoction, Yitangkang, Wenpi Fuzheng Decoction, Jiangtang Pills, Tangzhiping, Jiangtang Tiaozhi Fang, Dahuang Huanglian Xiexin Decoction, Heye Jiangzhi Decoction, Chaihu Sanren Decoction, Yangyin Jiangya Capsule, etc. These traditional Chinese medicines are mainly aimed at metabolic syndrome of yin deficiency, qi deficiency, excess heat, qi stagnation or blood stasis syndrome, but the therapeutic effect on the common dampness syndrome metabolic syndrome in clinical practice is poor. Therefore, it is necessary to develop a traditional Chinese medicine composition that can effectively treat dampness syndrome metabolic syndrome to meet the clinical medication needs. Summary of the invention

[0005] The first purpose of the present invention is to provide a Chinese medicinal composition for removing dampness from Yinling. The second purpose of the present invention is to provide a method for preparing the Chinese medicinal composition. The third purpose of the present invention is to provide an application of the Chinese medicinal composition.

[0006] According to the first aspect of the present invention, a Chinese medicine composition for removing dampness from Yinling is provided, the effective ingredients of which include the following raw materials in parts by weight: 30-60 parts of Poria cocos, 10-30 parts of Atractylodes macrocephala, 10-30 parts of Polyporus umbellatus, 10-30 parts of cinnamon twig, 5-10 parts of dried ginger, 10-30 parts of licorice, 10-30 parts of Artemisia capillaris, and 10-30 parts of Adenophora adenophora.

[0007] The present invention believes that the metabolic syndrome of dampness syndrome is caused by the spleen and stomach deficiency and the long-term effect of dampness and turbidity in the body. Insufficient innate endowment or poor postnatal care can lead to damage of the spleen and stomach, abnormal qi transformation, decreased transport and metaplasia of water and grain essence, accumulation in the body, and transformation into phlegm, dampness, turbidity and heat. If it flows in the blood vessels, blood sugar, blood lipids and uric acid will increase; if it accumulates in the middle jiao, obesity in the abdomen and buttocks will be seen; if it is stagnant in the liver and gallbladder, fatty liver is common; if the liver qi is not smooth, liver yang will rise and blood pressure will increase.

[0008] The prescription uses a lot of Poria cocos as the main drug. Poria cocos is sweet and mild in nature, and can invigorate the spleen, promote diuresis and eliminate dampness. It is combined with the adjuvant cinnamon twig, which is pungent and warm, and can open the bladder to help transform qi and promote diuresis, so that dampness can be transformed. The assistant is Atractylodes macrocephala, which is sweet, bitter and warm in nature, and can invigorate the middle jiao, and help the main drug Poria cocos to strengthen its ability to remove dampness, so as to eliminate the source of dampness. The assistant is Polyporus umbellatus, which is sweet, mild and mild in nature, can penetrate dampness and promote diuresis, and help the main drug Poria cocos to remove dampness without hurting the true yin. The assistant is dried ginger, which is pungent and hot, and can invigorate the spleen, warm the middle and eliminate dampness. The assistant is Artemisia capillaris, which is bitter, pungent and slightly cold, and can clear away heat and promote diuresis, and restrain the warm and dry nature of the above drugs. The assistant is Adenophora scabra, which is sweet, bitter and slightly cold, and can nourish Yin, ventilate and moisten dryness, and prevent excessive diuresis from damaging Yin fluid. Licorice is used as the guiding drug, which is sweet and mild in nature, and can invigorate the spleen, clear away heat and promote diuresis, and harmonize the drugs. The whole formula works together to strengthen the spleen, promote diuresis and eliminate dampness, warm the middle and benefit the stomach, and eliminate dampness and heat.

[0009] The raw material sources of the present invention are as follows:

[0010] Poria cocos: The dried sclerotium of the fungus Poriacocos (Schw.) Wolf of the Polyporaceae family.

[0011] Atractylodes: The rhizome of Atractylodes macrocephala Koidz, a plant of the genus Atractylodes in the Asteraceae family.

[0012] Poria: The dried sclerotium of the fungus Polyporus umbellatus (Pers) Fr. of the Polyporaceae family.

[0013] Cinnamon twig: The young branch of cinnamon Cinnamomum cassia Presl.

[0014] Dried ginger: the dried rhizome of ginger, Zingiber officinale Rosc., a plant of the Zingiberaceae family.

[0015] Licorice: The dried roots and rhizomes of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L., plants of the genus Glycyrrhiza in the family Leguminosae.

[0016] Artemisia capillaris: the dried aerial parts of Artemisia scoparza Waldst.et Kit. or Artemisia capillaris Thunb. of the Asteraceae family.

[0017] Glehnia littoralis: The root of Glehnia littoralis F.Schmidtex Miq., a plant of the genus Glehnia in the family Apiaceae.

[0018] In some embodiments, the active ingredients include the following raw materials in parts by weight: 48 parts of Poria cocos, 18 parts of Atractylodes macrocephala, 12 parts of Polyporus umbellatus, 12 parts of cinnamon twig, 8 parts of dried ginger, 12 parts of licorice, 15 parts of Artemisia capillaris, and 12 parts of Adenophora adenophora.

[0019] In some embodiments, pharmaceutically acceptable excipients may also be added.

[0020] In some embodiments, the auxiliary material is at least one of a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, an adsorption carrier, a surfactant, and a lubricant.

[0021] In some embodiments, the dosage form of the Chinese medicine composition is granules, decoction, paste, powder, tablet, pill or capsule.

[0022] According to a second aspect of the present invention, a method for preparing the above-mentioned Yinling Qushi Chinese medicine composition is provided. When the dosage form of the Chinese medicine composition is a granule, the preparation method comprises the following steps:

[0023] (1) The above raw material drug is decocted twice with water. For the first decoction, water equivalent to 10 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours, and a first decoction and a medicinal residue are obtained after separation; for the second decoction, the medicinal residue obtained after the first decoction is taken, water equivalent to 8 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.0 hour, and a second decoction and a medicinal residue are obtained after separation; the first decoction and the second decoction are combined to obtain a combined decoction;

[0024] (2) concentrating the combined decoction under reduced pressure to obtain a clear paste;

[0025] (3) adding auxiliary materials to the obtained clear paste, dissolving and mixing, sieving, and then spray drying to collect powder to obtain dry paste powder, wherein the spray drying process parameters are: inlet air temperature 165-195° C., outlet air temperature 80-105° C.;

[0026] (4) sieving the obtained dry paste powder and mixing it evenly to obtain an extraction intermediate;

[0027] (5) The obtained extraction intermediate is granulated into 12-40 mesh granules by dry method to obtain the product.

[0028] In some embodiments, in step (2), the combined decoction is concentrated under reduced pressure to a specific gravity of 1.08-1.10 at 65±5° C. to obtain a clear paste.

[0029] According to a third aspect of the present invention, there is provided use of the above-mentioned Yinling Qushi Chinese medicine composition in the preparation of a medicament for treating metabolic syndrome.

[0030] According to a fourth aspect of the present invention, there is provided use of the above-mentioned Yinling Qushi Chinese medicine composition in the preparation of a medicament for treating metabolic syndrome of dampness syndrome.

[0031] The beneficial effects of the present invention include:

[0032] (1) Clinical trials have shown that the Yinling Qushi Chinese medicine composition of the present invention can effectively reduce the BMI of people with metabolic syndrome of dampness syndrome, effectively improve the level of dampness syndrome, and at the same time have a more obvious effect on the decrease of waist circumference (WC) and hip circumference (HC), so that the body weight has a certain downward trend. The regulation of blood lipids is mainly to lower the level of triglycerides (TG) and increase the level of high-density lipoprotein cholesterol (HDL-C), and can significantly reduce the levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP). In terms of safety, no clear serious adverse events related to the Yinling Qushi Chinese medicine composition have been reported, indicating that the Yinling Qushi Chinese medicine composition of the present invention is safe. It can be seen that the Yinling Qushi Chinese medicine composition of the present invention has a good therapeutic effect on metabolic syndrome of dampness syndrome.

[0033] (2) The Yinling dehumidifying Chinese medicine composition of the present invention can invigorate the spleen, promote diuresis and eliminate dampness, warm the middle and benefit the stomach, and eliminate dampness and heat. It is mainly used to treat metabolic syndrome caused by dampness blocking the middle, spleen and stomach deficiency and coldness, resulting in poor circulation in the middle jiao, diffuse dampness, and dampness and heat. DETAILED DESCRIPTION

[0034] The present invention is further described in detail below in conjunction with specific examples, but the embodiments of the present invention are not limited thereto. The materials involved in the following examples can all be obtained from commercial channels.

[0035] Example 1

[0036] The preparation method of the Yinling Qushi Granules of this embodiment comprises the following steps:

[0037] (1) Weigh 48g of Poria cocos, 18g of Atractylodes macrocephala, 12g of Polyporus umbellatus, 12g of cinnamon twig, 8g of dried ginger, 12g of liquorice, 15g of Artemisia capillaris, and 12g of Adenophora scabra.

[0038] (2) The above raw material drug is decocted with water twice. For the first decoction, water equivalent to 10 times the total mass of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours. After separation, a first decoction and a medicinal residue are obtained; for the second decoction, the medicinal residue obtained after the first decoction is taken, water equivalent to 8 times the total mass of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.0 hour. After separation, a second decoction and a medicinal residue are obtained; the first decoction and the second decoction are combined to obtain a combined decoction.

[0039] (3) The combined decoction is concentrated under reduced pressure to a specific gravity of 1.09 (65±5°C) to obtain a clear paste.

[0040] (4) Add 6.85 g of auxiliary material maltodextrin MD15 to the obtained clear paste, dissolve and mix, pass through a 100-mesh sieve, and then spray dry. Collect powder in time to obtain dry paste powder, wherein the spray drying process parameters are: inlet air temperature 180°C, outlet air temperature 90°C.

[0041] (5) Sieve the obtained dry paste powder and mix it evenly to obtain an extraction intermediate.

[0042] (6) The obtained extraction intermediate is granulated into 40 mesh granules by dry method, and packaged in blank aluminum foil bags by spray printing. Each bag contains 5.2 g. When taking, 3 bags are taken at a time, twice a day.

[0043] Example 2

[0044] The preparation method of the Yinling Qushi Granules of this embodiment is similar to that of Example 1, except that, in step (1), 30 g of Poria cocos, 15 g of Atractylodes macrocephala, 10 g of Polyporus umbellatus, 10 g of Cassia twig, 5 g of Dry ginger, 10 g of Licorice root, 10 g of Artemisia capillaris, and 10 g of Adenophora australis are weighed.

[0045] Example 3

[0046] The preparation method of the Yinling Qushi Granules of this embodiment is similar to that of Example 1, except that, in step (1), 45 g of Poria cocos, 20 g of Atractylodes macrocephala, 15 g of Polyporus umbellatus, 15 g of Cassia twig, 10 g of Dry ginger, 15 g of Licorice root, 20 g of Artemisia capillaris, and 15 g of Adenophora australis are weighed.

[0047] Example 4

[0048] The preparation method of the Yinling Qushi Granules of this embodiment is similar to that of Example 1, except that, in step (1), 60 g of Poria cocos, 30 g of Atractylodes macrocephala, 20 g of Polyporus umbellatus, 20 g of Cassia twig, 10 g of Dry ginger, 20 g of Licorice root, 20 g of Artemisia capillaris, and 20 g of Adenophora australis are weighed.

[0049] In order to illustrate the therapeutic effect of the Yinling Qushi Chinese medicine composition of the present invention on metabolic syndrome (MetS), the following clinical trials were conducted.

[0050] 1. Research Design

[0051] Randomized, double-blind, placebo-controlled study.

[0052] 2. Diagnosis and inclusion and exclusion criteria

[0053] 1. Diagnostic criteria for metabolic syndrome

[0054] Refer to the diagnosis of MetS in the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 Edition)":

[0055] (1) Abdominal obesity (i.e. central obesity): WC ≥ 90 cm for men and ≥ 85 cm for women.

[0056] (2) Hyperglycemia: FPG ≥ 6.1 mmol / L or blood glucose ≥ 7.8 mmol / L 2 hours after glucose load and / or those who have been diagnosed with diabetes and are receiving treatment.

[0057] (3) Hypertension: blood pressure ≥130 / 85 mmHg and / or those who have been confirmed to have hypertension and received treatment.

[0058] (4) Fasting TG ≥1.70mmol / L.

[0059] (5) Fasting HDL-C <1.04mmol / L.

[0060] The diagnosis can be made if three or more of the above items are present.

[0061] 2. Diagnostic criteria for dampness syndrome

[0062] Refer to the typical dampness diagnosis criteria in the "Diagnostic Criteria for Dampness in Traditional Chinese Medicine V2.0" issued by the China Association of Traditional Chinese Medicine:

[0063] Typical dampness syndrome diagnostic criteria: Typical dampness syndrome can be diagnosed if any of the following conditions are met:

[0064] (1) It has 1 specificity index and 2 sensitivity indexes;

[0065] (2) Having two types of specific indicators;

[0066] (3) It has four sensitivity indicators.

[0067] The specificity and sensitivity indicators of dampness syndrome are shown in Table 1:

[0068] Table 1 Specificity and sensitivity indexes of dampness syndrome

[0069]

[0070]

[0071] Note 1: The specificity index is measured in “class”; the sensitivity index is measured in “item”;

[0072] Note 2: The severity classification of indicators can be found in the "Information Collection Table for Core Symptoms of Dampness Syndrome in Traditional Chinese Medicine" in the published group standard;

[0073] Note 3: For the diagnostic criteria of dampness syndrome, if the severity of any one of the specific indicators belongs to the same category and the severity of any one of the indicators meets the moderate or severe level, it can be judged that the specific indicators of this category are possessed; for the diagnostic criteria of typical dampness syndrome, if the specific indicators belong to the same category and the severity of any one of the indicators meets the moderate or severe level, the specific indicators of this category can be judged as possessing this category.

[0074] 3. Inclusion criteria

[0075] (1) 18-75 years old;

[0076] (2) Those who meet the diagnosis of typical dampness syndrome;

[0077] (3) Those who meet the diagnosis of metabolic syndrome;

[0078] (4) Those who voluntarily participate in this research project and sign the informed consent form.

[0079] 4. Exclusion criteria

[0080] (1) Patients with secondary abnormalities in blood sugar, blood lipids, and blood pressure caused by diseases such as nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, myeloma, glycogen storage disease, lipoatrophy, acute porphyria, and polycystic ovary syndrome;

[0081] (2) Patients with dysglycemia and dyslipidemia caused by drugs (phenothiazines, β-blockers, corticosteroids, etc.);

[0082] (3) patients whose SBP remains ≥180 mmHg or DBP remains ≥110 mHg after blood pressure treatment;

[0083] (4) patients whose blood glucose FPG remained ≥11.1mmol / L after drug treatment;

[0084] (5) patients with TC ≥ 6.22 mmol / L, LDL-C ≥ 4.92 mmol / L, or TG ≥ 3.39 mmol / L after oral medication;

[0085] (6) Patients with malignant tumors, severe heart diseases, blood system diseases, cerebrovascular accidents, severe trauma or major surgery;

[0086] (7) Those with allergic constitution or who may be allergic to this drug;

[0087] (8) Pregnant or lactating women or those who plan to become pregnant during the trial or whose spouses plan to become pregnant;

[0088] (9) Others who cannot be long-term partners.

[0089] 3. Intervention Plan

[0090] 1. Basic intervention measures

[0091] The basic treatment that the subjects received before participating in the trial will not be changed. That is, before participating in the trial, if the subjects have received conventional modern medical treatment, including oral lipid-lowering, blood pressure-lowering, blood sugar control and other drugs, their previous treatment plan will remain unchanged; if the subjects have not yet received regular treatment and their blood lipids, blood pressure, and blood sugar are within a safe range (that is, they have not reached the range specified by the exclusion criteria), they will not be given conventional Western medicine treatment.

[0092] 2. Group intervention measures

[0093] (1) The test group was given oral administration of Yinling Qushi Granules prepared in Example 1, 3 small bags (5.2 g / bag) at a time, i.e. 15.6 g / time, the Chinese medicine granules were dissolved in 200-300 mL of boiling water, stirred evenly and taken warm, twice a day, after breakfast and lunch. Yinling Qushi Granules were prepared by Jiangyin Tianjiang Pharmaceutical Co., Ltd.

[0094] (2) The control group was given oral placebo granules, and the dosage and frequency of administration were exactly the same as those of the experimental group, that is, 3 small bags at a time (5.2g / bag, 15.6g / time). The granules were dissolved in 200-300mL of boiling water, stirred evenly and taken warm, twice a day, after breakfast and lunch. The main ingredients of the placebo were starch, dextrin, edible coloring caramel coloring, and lemon yellow pigment. The outer packaging was exactly the same as that of Yinling Qushi Granules. The appearance, color, smell and taste of the placebo granules were basically the same as those of Yinling Qushi Granules, and the two were indistinguishable. The placebo granules were also prepared by Jiangyin Tianjiang Pharmaceutical Co., Ltd.

[0095] 3. Intervention cycle

[0096] The intervention period for both groups was 12 weeks.

[0097] IV. Evaluation Indicators

[0098] Assessments were conducted at baseline (0w), 4 weeks ± 5 days of intervention (4w), and 12 weeks ± 7 days of intervention (12w).

[0099] 1. Main efficacy indicators

[0100] Body mass index (BMI).

[0101] 2. Secondary efficacy indicators

[0102] (1) Dampness syndrome level: Dampness syndrome scale score.

[0103] (2) Other body shape related indicators: weight, waist circumference (WC), and hip circumference (HC).

[0104] (3) Lipid metabolism: triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C).

[0105] (4) Blood pressure: systolic blood pressure (SBP), diastolic blood pressure (DBP).

[0106] (5) Carbohydrate metabolism: fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), etc.

[0107] 3. Safety indicators

[0108] Safety evaluation included laboratory indicators (blood routine, liver and kidney function, urine routine), electrocardiogram examination and adverse events.

[0109] V. Statistical Methods

[0110] SPSS software was used for statistical analysis, and PPS set was used for efficacy evaluation.

[0111] Measurement data: Repeated measurement data (ie, the number of tests > 2 times) were analyzed by variance analysis of repeated measurement data if they obeyed normal distribution, and generalized estimating equations were used if they did not obey normal distribution. P < 0.05 indicated significant difference.

[0112] 6. Research Results

[0113] A total of 108 subjects were included, with 54 in the experimental group and 54 in the control group. Seven subjects dropped out of the experimental group and six subjects dropped out of the control group. Finally, 95 subjects were included in the analysis, including 47 in the experimental group and 48 in the control group.

[0114] 1. Baseline data

[0115] The comparison results of the age data of the two groups of subjects are shown in Table 2, the gender distribution is shown in Table 3, and the baseline comparison results of the outcome indicators are shown in Table 4.

[0116] Table 2 Comparison of age data between the two groups

[0117]

[0118] Table 3 Gender distribution of the two groups

[0119]

[0120]

[0121] Table 4 Comparison of baseline outcome indicators between the two groups ( / M(P25 ~P 75 ))

[0122] index Experimental group (N=47) Control group (N=48) t / Z P Weight(kg) 78.20(68.80~88.00) 75.10(70.38~85.78) -0.231 0.818 <![CDATA[BMI(kg / m 2 )]]> 28.45±3.03 28.37±3.13 0.123 0.903 WC(cm) 96.88±7.45 96.65±6.90 0.157 0.876 HC(cm) 103.05±0.625 101.98±7.77 0.740 0.461 TG (mmol / L) 2.30(2.04~2.83) 2.37(2.15~3.45) -1.050 0.294 TC(mmol / L) 5.41(4.70~6.35) 5.29(5.00~6.17) -0.261 0.794 HDL-C (mmol / L) 1.06(0.94~1.34) 1.16(0.98~1.29) -0.584 0.559 LDL-C (mmol / L) 3.80±1.21 3.60±1.01 0.923 0.358 FBG (mmol / L) 5.32(5.06~6.24) 5.30(5.05~6.19) -0.119 0.905 HbA1c (%) 5.90(5.60~6.30) 5.75(5.53~6.25) -1.565 0.118 SBP (mmHg) 139.00(130.00~147.00) 138.00(127.00~142.00) -1.505 0.132 DBP (mmHg) 85.96±11.48 84.48±10.14 0.666 0.507 Dampness syndrome score (points) 46.74±14.78 51.33±12.171 -1.654 0.102

[0123] As can be seen from Tables 2-4, the age, gender, and outcome indicators of the two groups of subjects were balanced before intervention and were comparable.

[0124] 2. Main outcome measures

[0125] The comparison results of BMI between the two groups are shown in Table 5:

[0126] Table 5 Comparison of BMI between the two groups (kg / m 2 , )

[0127] Group N 0w 4w 12w Difference before and after intervention <![CDATA[P 时间 ]]> Experimental Group 47 28.45±3.03 28.45±2.89 28.28±2.95 -0.166 0.027 Control group 48 28.37±3.13 28.45±3.33 28.40±3.32 0.096 0.095 Difference between groups - 0.08 -0.003 -0.113 - - F - 0.015 <0.001 0.031 - - <![CDATA[Partial η 2 > - <0.001 <0.001 <0.001 - - <![CDATA[P 组间 ]]> - 0.903 0.996 0.861 - -

[0128] As can be seen from Table 5, the BMI of the experimental group decreased significantly after intervention compared with the baseline period (P=0.027), while the BMI of the control group did not change significantly before and after intervention. This shows that the Yinling Qushi Chinese medicine composition of the present invention can effectively reduce the BMI of people with dampness syndrome MetS.

[0129] 3. Secondary outcome indicators

[0130] (1) Dampness syndrome scoring

[0131] The comparison results of the dampness syndrome level scores between the two groups are shown in Table 6:

[0132] Table 6 Comparison of dampness syndrome scores between the two groups (points, )

[0133]

[0134]

[0135] As can be seen from Table 6, the dampness level scores of the two groups decreased significantly after intervention (P<0.001), among which the improvement of dampness in the experimental group was more obvious, and the difference between the two groups was statistically significant (P<0.001). This shows that the dampness level of the two groups of subjects has improved, among which Yinling Qushi Granule can more effectively improve the dampness level score of the MetS population.

[0136] (2)Weight

[0137] The comparison results of the two groups' body weights are shown in Table 7:

[0138] Table 7 Comparison of body weight between the two groups (kg, M (P 25 ~P 75 ))

[0139]

[0140] As can be seen from Table 7, the weight of the experimental group decreased after intervention compared with the baseline (P>0.05), while the weight of the control group did not change significantly before and after intervention, indicating that the Yinling Qushi Chinese medicine composition of the present invention can reduce the weight of people with MetS syndrome after intervention.

[0141] (3) Waist and hip circumference

[0142] The comparison results of waist circumference (WC) and hip circumference (HC) of the two groups are shown in Table 8:

[0143] Table 8 Comparison of WC and HC between the two groups (cm, M (P 25 ~P 75 ))

[0144]

[0145] As can be seen from Table 8, at 12 weeks, the waist circumference difference between the two groups was statistically significant (P=0.017); the waist circumference difference before and after the intervention in the experimental group was statistically significant (P<0.001), while the waist circumference difference before and after the intervention in the control group was not statistically significant (P=0.693). This shows that the Yinling Qushi Chinese medicine composition of the present invention can effectively reduce the waist circumference of people with dampness syndrome MetS.

[0146] It can also be seen from Table 8 that at 12 weeks, the hip circumference of the test group was lower than that at 0 weeks, and the difference in hip circumference before and after the intervention was statistically significant (P=0.004), while the hip circumference of the control group showed an upward trend after the intervention, but the difference between the two was not statistically significant. This shows that the Yinling Qushi Chinese medicine composition of the present invention can effectively reduce the hip circumference of the MetS population with dampness syndrome.

[0147] (4) Triglycerides

[0148] The comparison results of triglyceride (TG) in the two groups are shown in Table 9:

[0149] Table 9 Comparison of TG between the two groups (mmol / L, M (P 25 ~P 75 ))

[0150]

[0151] As can be seen from Table 9, the difference in TG between the two groups after intervention was statistically significant (P 组间 =0.049). This suggests that the Yinling Qushi Chinese medicine composition has a better regulatory effect on TG in the dampness syndrome MetS population compared with the placebo.

[0152] (5) High-density lipoprotein cholesterol, low-density lipoprotein cholesterol and total cholesterol

[0153] The comparison results of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in the two groups are shown in Table 10:

[0154] Table 10 Comparison of HDL-C, LDL-C and TC between the two groups (mmol / L, )

[0155]

[0156] As can be seen from Table 10, the difference in HDL-C before and after the intervention in the experimental group was statistically significant (P = 0.014), that is, HDL-C increased significantly after the intervention of Yinling Qushi Granules, which suggests that the Yinling Qushi Chinese medicine composition can effectively improve the HDL-C level of the MetS population with dampness syndrome. The HDL-C of the control group decreased significantly after 12 weeks of placebo intervention, and the difference was statistically significant (P = 0.026).

[0157] It can also be seen from Table 10 that there was no significant change in LDL-C and TC levels in the two groups before and after the intervention, indicating that these two indicators were not significantly improved after the intervention.

[0158] (6) Blood pressure

[0159] The comparison results of systolic blood pressure (SBP) between the two groups are shown in Table 11:

[0160] Table 11 Comparison of SBP between the two groups (mmHg, M (P 25 ~P 75 ))

[0161]

[0162] As can be seen from Table 11, the difference in SBP between the two groups at 12 weeks was statistically significant (P=0.032); the difference in SBP before and after the intervention in the experimental group was statistically significant (P<0.001), while the difference in SBP before and after the intervention in the control group was not statistically significant (P=0.347). This suggests that the Yinling Qushi Chinese medicine composition of the present invention can effectively reduce the SBP level of people with dampness syndrome MetS.

[0163] The comparison results of diastolic blood pressure (DBP) between the two groups are shown in Table 12:

[0164] Table 12 Comparison of DBP between the two groups (mmHg, )

[0165] Group N 0w 4w 12w Difference before and after intervention <![CDATA[P 时间 ]]> Experimental Group 47 85.96±11.48 80.91±9.40 81.36±9.33 -4.596 <![CDATA[<0.001 * ]]> Control group 48 84.48±10.14 82.94±12.15 84.02±8.81 -0.458 1.000 Difference between groups - 1.478 -2.023 -2.659 - - F - 1.348 2.500 6.214 - - <![CDATA[Partial η 2 > - <0.001 <0.001 <0.001 - - <![CDATA[P 组间 ]]> - 0.247 0.115 <![CDATA[0.013 * ]]> - -

[0166] As can be seen from Table 12, the difference in DBP between the two groups at 12 weeks was statistically significant (P=0.013<0.05); the difference in DBP before and after the intervention in the experimental group was statistically significant (P<0.001), and the difference in DBP before and after the intervention in the control group was not statistically significant (P>0.05). This suggests that the Yinling Qushi Chinese medicine composition of the present invention can effectively reduce the DBP level of people with dampness syndrome MetS.

[0167] (7) Fasting blood glucose and glycosylated hemoglobin

[0168] The comparison results of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) between the two groups are shown in Table 13:

[0169] Table 13 Comparison of FBG and HbA1c between the two groups (M (P 25 ~P 75 ))

[0170]

[0171]

[0172] As can be seen from Table 13, there was no significant change in the FBG and HbA1c levels in the two groups before and after the intervention, indicating that these two indicators were not significantly improved after the intervention.

[0173] 4. Safety evaluation

[0174] Safety evaluation included laboratory indicators (blood routine, liver and kidney function, urine routine), electrocardiogram and adverse events. The safety analysis set was used for analysis, including all medication cases (including 13 cases of dropout), a total of 108 cases, including 54 cases in the experimental group and 54 cases in the control group. During the 12-week treatment period, there were no obvious abnormal changes in the results of blood routine, liver function (AST, ALT), renal function (creatinine, urea), urine routine and electrocardiogram in the two groups of subjects. During the trial, a total of 15 subjects experienced adverse events, including 6 cases (12.77%) in the experimental group and 9 cases (18.75%) in the control group. Among them, there was 1 serious adverse event in the experimental group, which was subject No. 18. On the 16th day of intervention, a liver tumor (4mm) was found during physical examination. It was diagnosed as early liver cancer. After further surgical treatment in hospital, the general condition was good. It was determined that there was no direct relationship with the trial medication. The main reasons included that the subjects took the medication for a short time and the onset of liver cancer was hidden. The remaining 14 adverse events were transient and could be relieved on their own or after symptomatic treatment. They did not affect daily work and life. After comprehensive evaluation based on factors such as the peak influenza season during the trial, it was determined that 2 of them might be related to the trial drugs (hemorrhoidal bleeding and eczema) and were expected adverse events. The main reason was that the warm Chinese medicines such as cinnamon twig in the trial drugs might cause warmth and dryness in people with a previously damp and hot constitution. The remaining 12 cases might or definitely have nothing to do with the trial drugs.

[0175] Therefore, no serious adverse events related to Yinling Qushi Granules have been reported so far, and the subjects did not experience liver and kidney function damage after intervention, indicating that Yinling Qushi Granules are safe.

[0176] 5. Conclusion

[0177] The clinical trial results show that the Yinling Qushi Chinese medicine composition of the present invention can effectively reduce the BMI of people with metabolic syndrome of dampness syndrome, effectively improve the level of dampness syndrome, and at the same time have a more obvious effect on the decrease of waist circumference (WC) and hip circumference (HC), so that the body weight has a certain downward trend, and the regulation of blood lipids is mainly to lower the level of triglycerides (TG) and increase the level of high-density lipoprotein cholesterol (HDL-C), which can significantly reduce the levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP). In terms of safety, no clear serious adverse events related to the Yinling Qushi Chinese medicine composition have been reported, indicating that the Yinling Qushi Chinese medicine composition of the present invention is safe. It can be seen that the Yinling Qushi Chinese medicine composition of the present invention has a good therapeutic effect on metabolic syndrome of dampness syndrome.

[0178] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. Yinling dehumidifying Chinese medicine composition, It is characterized in that The effective ingredients include the following raw materials in parts by weight: 30-60 parts of Poria cocos, 10-30 parts of Atractylodes macrocephala, 10-30 parts of Polyporus umbellatus, 10-30 parts of cinnamon twig, 5-10 parts of dried ginger, 10-30 parts of liquorice, 10-30 parts of Artemisia capillaris, and 10-30 parts of Adenophora adenophora.

2. The Yinling dehumidifying Chinese medicine composition according to claim 1, It is characterized in that Its effective ingredients include the following raw materials in parts by weight: 48 parts of Poria cocos, 18 parts of Atractylodes macrocephala, 12 parts of Polyporus umbellatus, 12 parts of cinnamon twig, 8 parts of dried ginger, 12 parts of liquorice, 15 parts of Artemisia capillaris, and 12 parts of Adenophora adenophora.

3. The Yinling dehumidifying Chinese medicine composition according to claim 1 or 2, It is characterized in that Pharmaceutically acceptable excipients may also be added.

4. The Yinling dehumidifying Chinese medicine composition according to claim 3, It is characterized in that The auxiliary material is at least one of a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, an adsorption carrier, a surfactant, and a lubricant.

5. The Yinling dehumidifying Chinese medicine composition according to claim 1 or 2, It is characterized in that The dosage form of the Chinese medicine composition is granules, decoction, paste, powder, tablet, pill or capsule.

6. A method for preparing the Yinling Qushi Chinese medicine composition according to any one of claims 1 to 5, It is characterized in that When the dosage form of the Chinese medicine composition is granules, the preparation method thereof comprises the following steps: (1) The above raw material drug is decocted twice with water. For the first decoction, water equivalent to 10 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours, and a first decoction and a medicinal residue are obtained after separation; for the second decoction, the medicinal residue obtained after the first decoction is taken, water equivalent to 8 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.0 hour, and a second decoction and a medicinal residue are obtained after separation; the first decoction and the second decoction are combined to obtain a combined decoction; (2) concentrating the combined decoction under reduced pressure to obtain a clear paste; (3) adding auxiliary materials to the obtained clear paste, dissolving and mixing, sieving, and then spray drying to collect powder to obtain dry paste powder, wherein the spray drying process parameters are: inlet air temperature 165-195° C., outlet air temperature 80-105° C.; (4) sieving the obtained dry paste powder and mixing it evenly to obtain an extraction intermediate; (5) The obtained extraction intermediate is granulated into 12-40 mesh granules by dry method to obtain the product.

7. The preparation method according to claim 6, It is characterized in that In step (2), the combined decoction is concentrated under reduced pressure to a specific gravity of 1.08-1.10 at 65±5° C. to obtain a clear paste.

8. Use of the Yinling Qushi Chinese medicine composition according to any one of claims 1 to 5 in the preparation of a medicament for treating metabolic syndrome.

9. Use of the Yinling Qushi Chinese medicine composition according to any one of claims 1 to 5 in the preparation of a medicament for treating metabolic syndrome of dampness syndrome.

Citation Information

Patent Citations

  • Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof

    CN102028900A

  • Traditional Chinese medicine composition for treating spleen deficiency dampness-overabundance type sugar tolerance reduction

    CN104352714A

  • Traditional Chinese medicine formula for treating diabetes caused by retention of water-dampness

    CN109985143A

  • Total components and blood-entering components of herba artemisiae scopariae dampness-clearing granules and detection method of total components and blood-entering components

    CN119619361A

Cited By

  • Total components and blood-entering components of herba artemisiae scopariae dampness-clearing granules and detection method of total components and blood-entering components

    CN119619361A